Eli Lilly lifts profit outlook as obesity drug sales grow
Eli Lilly raised its 2026 profit outlook after reporting better-than-expected first quarter results. Strong demand for its obesity drugs drove the growth.
Xurve View
Insights:
Xurve View
ELI LILLY & CO raised its 2026 adjusted profit forecast to $35.50–$37.00 per share after beating first-quarter earnings expectations. Q1 adjusted profit reached $8.55 per share, exceeding the $6.66 estimate as Mounjaro sales hit $8.7B. Investors are tracking whether Lilly can maintain volume growth to offset lower drug prices in the United_States.
